Mario Enrique Rendón-Macías, Heladia García, Miguel Ángel Villasís-Keever
The practice of evidence-based medicine includes the critical analysis of clinical research studies, and, within it, the interpretation of the results reported. In addition, to statistical data, there are estimators that can help clinicians transfer research findings to routine clinical practice. These estimators are measures of risk, association, and impact. Risk measures report current uncertainty or probability (prevalence of a disease, sensitivity, specificity) or for future events (cumulative incidence, incidence density). Measures of association are related to the identification of the risk in order to determine whether certain factors increase or decrease the probability of development of a disease (relative risk, odds ratio, hazard ratio). While measures of impact allow, among other things, to estimate the effect of a treatment (relative risk reduction, absolute risk reduction, number needed to treat). In this review, each of these estimators is described, defined, and presented with examples.
{"title":"[Risk, association, and impact measures in clinical research studies. How to interpret them for their application in medical care].","authors":"Mario Enrique Rendón-Macías, Heladia García, Miguel Ángel Villasís-Keever","doi":"10.29262/ram.v68i1.886","DOIUrl":"https://doi.org/10.29262/ram.v68i1.886","url":null,"abstract":"<p><p>The practice of evidence-based medicine includes the critical analysis of clinical research studies, and, within it, the interpretation of the results reported. In addition, to statistical data, there are estimators that can help clinicians transfer research findings to routine clinical practice. These estimators are measures of risk, association, and impact. Risk measures report current uncertainty or probability (prevalence of a disease, sensitivity, specificity) or for future events (cumulative incidence, incidence density). Measures of association are related to the identification of the risk in order to determine whether certain factors increase or decrease the probability of development of a disease (relative risk, odds ratio, hazard ratio). While measures of impact allow, among other things, to estimate the effect of a treatment (relative risk reduction, absolute risk reduction, number needed to treat). In this review, each of these estimators is described, defined, and presented with examples.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"65-75"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39248056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martín Bedolla-Barajas, Jaime Morales-Romero, Juan Carlos López-Hernández, Tonatiuh Ramses Bedolla-Pulido, Lourdes Fabiola García-Padilla, Martín Robles-Figueroa, Miriam Montzerrat Flores-Razo
Background: The impact of obesity on the severity of asthma continues to be a cause of controversy.
Objective: To compare the severity of asthma and asthma control in obese patients with non-obese patients.
Methods: A cross-sectional study which included 188 patients with asthma, of ≥ 18 years of age, who were selected consecutively. The patients were categorized and compared based on the presence or absence of obesity. In order to establish an association between variables, logistic regression analyses were performed.
Results: In total, 111/188 of the patients had obesity; these patients were older than those without obesity (35.9 ± 15.3 years vs. 44.4 ± 13.8 years, p <0.001). No significant difference was observed in the groups regarding sex, total IgE serum concentration, peripheral blood eosinophil count, personal history of atopic diseases, frequency of allergic sensitization, hospitalization for asthma, and asthma control. Overall, obesity was significantly associated with moderate-severe asthma (OR = 1.82, p = 0.047), but not with asthma control (p = 0.094).
Conclusions: Our results suggest that patients with asthma and obesity are older and that their pulmonary function is worse, which is reflected in a greater level of severity of asthma.
{"title":"[Obesity in adulthood is associated with the severity of asthma, but not with asthma control].","authors":"Martín Bedolla-Barajas, Jaime Morales-Romero, Juan Carlos López-Hernández, Tonatiuh Ramses Bedolla-Pulido, Lourdes Fabiola García-Padilla, Martín Robles-Figueroa, Miriam Montzerrat Flores-Razo","doi":"10.29262/ram.v68i1.756","DOIUrl":"https://doi.org/10.29262/ram.v68i1.756","url":null,"abstract":"<p><strong>Background: </strong>The impact of obesity on the severity of asthma continues to be a cause of controversy.</p><p><strong>Objective: </strong>To compare the severity of asthma and asthma control in obese patients with non-obese patients.</p><p><strong>Methods: </strong>A cross-sectional study which included 188 patients with asthma, of ≥ 18 years of age, who were selected consecutively. The patients were categorized and compared based on the presence or absence of obesity. In order to establish an association between variables, logistic regression analyses were performed.</p><p><strong>Results: </strong>In total, 111/188 of the patients had obesity; these patients were older than those without obesity (35.9 ± 15.3 years vs. 44.4 ± 13.8 years, p <0.001). No significant difference was observed in the groups regarding sex, total IgE serum concentration, peripheral blood eosinophil count, personal history of atopic diseases, frequency of allergic sensitization, hospitalization for asthma, and asthma control. Overall, obesity was significantly associated with moderate-severe asthma (OR = 1.82, p = 0.047), but not with asthma control (p = 0.094).</p><p><strong>Conclusions: </strong>Our results suggest that patients with asthma and obesity are older and that their pulmonary function is worse, which is reflected in a greater level of severity of asthma.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"26-34"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39248059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Catalina Rincón-Pérez, Carmen Gabriela Torres-Alarcón, Saraid Cerda, Juan Gabriel Maldonado-Hernández, Patricia Marín-Ambrocio, Rocío Tovar-Franco
BACKGROUND Information about the clinical and epidemiological characteristics of atopic dermatitis (AD) is essential to generate knowledge of the disease and its socioeconomic impact. OBJECTIVE To describe the clinical characteristics of the patients of an atopic dermatitis clinic. METHODS An observational, retrospective, and cross-sectional study. Demographic data, severity of the AD (according to the Eczema Area Severity Index), clinical phenotype, total serum IgE, the presence of allergic and non-allergic comorbidities, as well as of anxiety and depression, were recorded by means of targeted questionnaire and Hamilton Scale. Descriptive and inferential statistics were obtained, considering a statistical significance associated with a value of p <0.05. RESULTS 187 patients were included; the median age was 12 years with a range of 1-87 years. Differences were found regarding sex and severity (p < 0.05). Mild forms of AD were presented in 57.8% of the patients, moderate forms in 20.9%, and severe forms in 21.4%. The severity was associated with allergic comorbidities such as asthma (p = 0.001) and allergic conjunctivitis (p <0.001). Severe AD was associated with a state of anxiety and depression (p <0.05), as well as with ocular affectation (p<0.001). CONCLUSION The pediatric population is the most affected by AD; however, in the adult population, the severe form associated with allergic comorbidities is observed.
{"title":"[Clinical characteristics of a population with atopic dermatitis in a tertiary center].","authors":"Catalina Rincón-Pérez, Carmen Gabriela Torres-Alarcón, Saraid Cerda, Juan Gabriel Maldonado-Hernández, Patricia Marín-Ambrocio, Rocío Tovar-Franco","doi":"10.29262/ram.v68i1.843","DOIUrl":"https://doi.org/10.29262/ram.v68i1.843","url":null,"abstract":"BACKGROUND\u0000Information about the clinical and epidemiological characteristics of atopic dermatitis (AD) is essential to generate knowledge of the disease and its socioeconomic impact.\u0000\u0000\u0000OBJECTIVE\u0000To describe the clinical characteristics of the patients of an atopic dermatitis clinic.\u0000\u0000\u0000METHODS\u0000An observational, retrospective, and cross-sectional study. Demographic data, severity of the AD (according to the Eczema Area Severity Index), clinical phenotype, total serum IgE, the presence of allergic and non-allergic comorbidities, as well as of anxiety and depression, were recorded by means of targeted questionnaire and Hamilton Scale. Descriptive and inferential statistics were obtained, considering a statistical significance associated with a value of p <0.05.\u0000\u0000\u0000RESULTS\u0000187 patients were included; the median age was 12 years with a range of 1-87 years. Differences were found regarding sex and severity (p < 0.05). Mild forms of AD were presented in 57.8% of the patients, moderate forms in 20.9%, and severe forms in 21.4%. The severity was associated with allergic comorbidities such as asthma (p = 0.001) and allergic conjunctivitis (p <0.001). Severe AD was associated with a state of anxiety and depression (p <0.05), as well as with ocular affectation (p<0.001).\u0000\u0000\u0000CONCLUSION\u0000The pediatric population is the most affected by AD; however, in the adult population, the severe form associated with allergic comorbidities is observed.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"12-25"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39250125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel O Vazquez, Darío O Josviack, Claudio A Fantini, Natalia L Fili, Alejandro M Berardi, Ricardo D Zwiener, René A Baillieau, Gonzalo F Chorzepa, Gabriel O Fueyo, Claudia M García, Gabriel Gattolin, Mónica B Marocco, Claudio A S Parisi, Marcelo D Strass, José E Fabiani
Objectives: Hereditary angioedema (HAE) is a rare disease. During the last years, many studies and advances have been developed with the aim of better understanding the pathophysiology, as well as optimizing patient management. Several international working groups have attempted to clarify and standardize the care of HAE communicated as guidelines and consensus recommendations. We considered necessary to provide recommendations for the diagnosis and treatment of patients with HAE in Argentina.
Methods: A group of specialists of allergy and immunology from Argentina by using the online surveys methodology as well as face to face meetings developed the intended consensus.
Results: Recommendations were established based on published evidence and the expert opinion. The consensus focused on diagnosis, acute management of attacks, short and long-term prophylaxis, special situations (pediatrics and pregnancy) and disease management considering the health care system in Argentina.
Conclusion: The recommendations established in this consensus guidelines will optimize the management of patients with HAE in Argentina.
{"title":"[Argentine Consensus of the Diagnosis and Treatment of Hereditary Angioedema].","authors":"Daniel O Vazquez, Darío O Josviack, Claudio A Fantini, Natalia L Fili, Alejandro M Berardi, Ricardo D Zwiener, René A Baillieau, Gonzalo F Chorzepa, Gabriel O Fueyo, Claudia M García, Gabriel Gattolin, Mónica B Marocco, Claudio A S Parisi, Marcelo D Strass, José E Fabiani","doi":"10.29262/ram.v68i6.914","DOIUrl":"https://doi.org/10.29262/ram.v68i6.914","url":null,"abstract":"<p><strong>Objectives: </strong>Hereditary angioedema (HAE) is a rare disease. During the last years, many studies and advances have been developed with the aim of better understanding the pathophysiology, as well as optimizing patient management. Several international working groups have attempted to clarify and standardize the care of HAE communicated as guidelines and consensus recommendations. We considered necessary to provide recommendations for the diagnosis and treatment of patients with HAE in Argentina.</p><p><strong>Methods: </strong>A group of specialists of allergy and immunology from Argentina by using the online surveys methodology as well as face to face meetings developed the intended consensus.</p><p><strong>Results: </strong>Recommendations were established based on published evidence and the expert opinion. The consensus focused on diagnosis, acute management of attacks, short and long-term prophylaxis, special situations (pediatrics and pregnancy) and disease management considering the health care system in Argentina.</p><p><strong>Conclusion: </strong>The recommendations established in this consensus guidelines will optimize the management of patients with HAE in Argentina.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 Suppl 2 ","pages":"s1-s22"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39304383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahora, aun cuando no contamos con un tratamiento específico, tenemos pruebas que nos permiten identificar rápidamente los casos de COVID-19 y ya se están aplicando vacunas que previenen la mortalidad causada por SARS-CoV-2, algunas basadas en técnicas desarrolladas en la investigación del virus de la inmunodeficiencia humana.
{"title":"[Vaccine against the infodemic].","authors":"Eric Martínez-Infante","doi":"10.29262/ram.v68i1.910","DOIUrl":"https://doi.org/10.29262/ram.v68i1.910","url":null,"abstract":"Ahora, aun cuando no contamos con un tratamiento específico, tenemos pruebas que nos permiten identificar rápidamente los casos de COVID-19 y ya se están aplicando vacunas que previenen la mortalidad causada por SARS-CoV-2, algunas basadas en técnicas desarrolladas en la investigación del virus de la inmunodeficiencia humana.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39250123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Armando Partida-Gaytán, Luis Torre-Bouscoulet, M. Macías, Alejandro Raimondi, E. Pizzichini
Severe asthma is a heterogeneous and complex disease that affects approximately 5% of patients with asthma and is associated with a significant burden of symptoms, frequent severe exacerbations, and negative impacts on functionality and quality of life. Different innovation strategies have updated the therapeutic options available for these patients, but monoclonal antibodies represent the alternative with the greatest clinical relevance. It is important that the asthma specialist is kept up-to-date to correctly identify those patients who may benefit from treatment with these medications. This article provides an up-to-date and practical review focused on mepolizumab, a humanized anti-IL-5 monoclonal antibody approved as an add-on treatment in patients with severe eosinophilic asthma. In this document, a synthesis of the evidence of efficacy, safety and effectiveness of mepolizumab has been made with the aim of providing a consultation and decision support tool for the specialist who evaluates, diagnoses and treats patients with severe asthma. In controlled conditions of clinical trials and in real-life studies, mepolizumab has been documented to consistently and significantly reduce asthma exacerbations, improve disease control, and patients’ quality of life; likewise, it decreases the dose or makes possible the withdrawal of systemic corticosteroids.
{"title":"Mepolizumab para el tratamiento de asma grave eosinofílica","authors":"Armando Partida-Gaytán, Luis Torre-Bouscoulet, M. Macías, Alejandro Raimondi, E. Pizzichini","doi":"10.29262/RAM.V67I7.780","DOIUrl":"https://doi.org/10.29262/RAM.V67I7.780","url":null,"abstract":"Severe asthma is a heterogeneous and complex disease that affects approximately 5% of patients with asthma and is associated with a significant burden of symptoms, frequent severe exacerbations, and negative impacts on functionality and quality of life. Different innovation strategies have updated the therapeutic options available for these patients, but monoclonal antibodies represent the alternative with the greatest clinical relevance. It is important that the asthma specialist is kept up-to-date to correctly identify those patients who may benefit from treatment with these medications. This article provides an up-to-date and practical review focused on mepolizumab, a humanized anti-IL-5 monoclonal antibody approved as an add-on treatment in patients with severe eosinophilic asthma. In this document, a synthesis of the evidence of efficacy, safety and effectiveness of mepolizumab has been made with the aim of providing a consultation and decision support tool for the specialist who evaluates, diagnoses and treats patients with severe asthma. In controlled conditions of clinical trials and in real-life studies, mepolizumab has been documented to consistently and significantly reduce asthma exacerbations, improve disease control, and patients’ quality of life; likewise, it decreases the dose or makes possible the withdrawal of systemic corticosteroids.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90372619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. E. Arablin-Oropeza, Víctor González-Uribe, B. D. Del Río-Navarro, A. García-González, E. M. Navarrete-Rodríguez, A. Valencia
Dupilumab is a fully human monoclonal antibody against the interleukin (IL)-4 and IL-4/IL-13 receptor complexes. These are key cytokines in driving type 2 inflammation, a dominant and largely inflammatory pathway in asthma. Trials evaluating the efficacy of dupilumab in asthma include three pivotal, placebo-controlled, phase 2b or 3 trials of 24-52 weeks treatment duration in patients aged below 12 years with moderate-to severe asthma (inadequately controlled with medium-to-high dose inhaled corticosteroids) or severe asthma (dependent on oral corticosteroids for control). In these studies, adding subcutaneous dupilumab to background therapy was generally well tolerated and reduced the rate of severe asthma exacerbations, improved lung function, as well as asthma control and, health-related quality of life, and enabled oral corticosteroids maintenance doses to be reduced without impacting asthma control. Dupilumab displayed efficacy across various patient subgroups, although those with heightened type 2 immune activity, tended to have a more prominent treatment benefit. Dupilumab is consequently widely indicated (and a valuable treatment option) as an add-on therapy in patients aged below 12 years who have severe/moderate-to-severe asthma with a type 2 inflammation/eosinophilic phenotype despite conventional treatments or have oral corticosteroids-dependent asthma.
{"title":"Dupilumab en el tratamiento del asma","authors":"S. E. Arablin-Oropeza, Víctor González-Uribe, B. D. Del Río-Navarro, A. García-González, E. M. Navarrete-Rodríguez, A. Valencia","doi":"10.29262/RAM.V67I7.779","DOIUrl":"https://doi.org/10.29262/RAM.V67I7.779","url":null,"abstract":"Dupilumab is a fully human monoclonal antibody against the interleukin (IL)-4 and IL-4/IL-13 receptor complexes. These are key cytokines in driving type 2 inflammation, a dominant and largely inflammatory pathway in asthma. Trials evaluating the efficacy of dupilumab in asthma include three pivotal, placebo-controlled, phase 2b or 3 trials of 24-52 weeks treatment duration in patients aged below 12 years with moderate-to severe asthma (inadequately controlled with medium-to-high dose inhaled corticosteroids) or severe asthma (dependent on oral corticosteroids for control). In these studies, adding subcutaneous dupilumab to background therapy was generally well tolerated and reduced the rate of severe asthma exacerbations, improved lung function, as well as asthma control and, health-related quality of life, and enabled oral corticosteroids maintenance doses to be reduced without impacting asthma control. Dupilumab displayed efficacy across various patient subgroups, although those with heightened type 2 immune activity, tended to have a more prominent treatment benefit. Dupilumab is consequently widely indicated (and a valuable treatment option) as an add-on therapy in patients aged below 12 years who have severe/moderate-to-severe asthma with a type 2 inflammation/eosinophilic phenotype despite conventional treatments or have oral corticosteroids-dependent asthma.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79685808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antecedentes: El trimetoprim con sulfametoxazol (TMP/SMX) es el farmaco de eleccion en prevalencia de VIH para la profilaxis de comorbilidades asociadas al SIDA. Objetivo : Comparar la eficacia y seguridad de 2 esquemas de desensibilizacion a Trimetroprim con Sulfametoxazol en pacientes con VIH. Material y metodos: Se realizo estudio de marzo del 2018 a octubre del 2019, se incluyeron pacientes con VIH (+) que presentaron alguna reaccion adversa en piel a TMT-SMX. 15 recibieron el esquema 1 de desensibilizacion de 10 dias de duracion en pacientes de consulta externa y en 5 se utilizo el esquema 2, de 6 h de duracion. Resultados: En los 20 pacientes, hubo un promedio de edad para el esquema 1 de 27.4 + 5.7 anos y para el esquema (2) 33.6 + 8 anos. Las variables demograficas, clinicas e inmunologicas en estado basal, no mostraron diferencias significativas p>0.05 entre ambos grupos, correspondientes a cada esquema. En ambos grupos se obtuvo eficacia del 100% y en cuanto a seguridad solo en el grupo 1, hubo 3 pacientes que presentaron rash y prurito que no amerito la suspension del procedimiento, se regreso a la dosis previa tolerada y posteriormente se continuo el procedimiento de desensibilizacion. Conclusiones: En los pacientes con VIH (+), las reacciones adversas a TMP/SMX, son frecuentes, y los 2 procedimientos de desensibilizacion utilizados en este trabajo mostraron eficacia y seguridad.
{"title":"Comparación de la Eficacia y seguridad de 2 esquemas de desensibilización a Trimetoprim con Sulfametoxazol en pacientes con VIH.","authors":"María del Rocio Ruenes Morales","doi":"10.29262/RAM.V67I1.745","DOIUrl":"https://doi.org/10.29262/RAM.V67I1.745","url":null,"abstract":"Antecedentes: El trimetoprim con sulfametoxazol (TMP/SMX) es el farmaco de eleccion en prevalencia de VIH para la profilaxis de comorbilidades asociadas al SIDA. Objetivo : Comparar la eficacia y seguridad de 2 esquemas de desensibilizacion a Trimetroprim con Sulfametoxazol en pacientes con VIH. Material y metodos: Se realizo estudio de marzo del 2018 a octubre del 2019, se incluyeron pacientes con VIH (+) que presentaron alguna reaccion adversa en piel a TMT-SMX. 15 recibieron el esquema 1 de desensibilizacion de 10 dias de duracion en pacientes de consulta externa y en 5 se utilizo el esquema 2, de 6 h de duracion. Resultados: En los 20 pacientes, hubo un promedio de edad para el esquema 1 de 27.4 + 5.7 anos y para el esquema (2) 33.6 + 8 anos. Las variables demograficas, clinicas e inmunologicas en estado basal, no mostraron diferencias significativas p>0.05 entre ambos grupos, correspondientes a cada esquema. En ambos grupos se obtuvo eficacia del 100% y en cuanto a seguridad solo en el grupo 1, hubo 3 pacientes que presentaron rash y prurito que no amerito la suspension del procedimiento, se regreso a la dosis previa tolerada y posteriormente se continuo el procedimiento de desensibilizacion. Conclusiones: En los pacientes con VIH (+), las reacciones adversas a TMP/SMX, son frecuentes, y los 2 procedimientos de desensibilizacion utilizados en este trabajo mostraron eficacia y seguridad.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74550294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
En el Mexico antiguo se tiene conocimiento de enfermedades propias del sistema respiratorio que fueron una causa importante de mortalidad en la poblacion. Severas epidemias en el siglo XVI asolaron y produjeron la muerte a nueve de cada diez indigenas, los medicos prehispanicos se desempenaban como medicos-hechiceros y eran los que atendian las enfermedades fisicas y espirituales que aquejaban a la poblacion. Se ha identificado un conocimiento medico importante propio de cada cultura, que explicaba las enfermedades dependiendo sus creencias religiosas e intentando resolver los problemas de salud que aquejaban en esa epoca.
{"title":"Una breve mirada a las enfermedades respiratorias en la época prehispánica en México","authors":"Guillermo Velázquez Sámano","doi":"10.29262/RAM.V67I1.793","DOIUrl":"https://doi.org/10.29262/RAM.V67I1.793","url":null,"abstract":"En el Mexico antiguo se tiene conocimiento de enfermedades propias del sistema respiratorio que fueron una causa importante de mortalidad en la poblacion. Severas epidemias en el siglo XVI asolaron y produjeron la muerte a nueve de cada diez indigenas, los medicos prehispanicos se desempenaban como medicos-hechiceros y eran los que atendian las enfermedades fisicas y espirituales que aquejaban a la poblacion. Se ha identificado un conocimiento medico importante propio de cada cultura, que explicaba las enfermedades dependiendo sus creencias religiosas e intentando resolver los problemas de salud que aquejaban en esa epoca.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84212543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Food allergy is an immune reaction that occurs frequently in pediatric age, its prevalence is higher in industrialized countries, affecting 8% of the population, the most frequently involved foods are milk, hen’s egg, soybeans, peanuts, fish, wheat, seafood and tree nuts. Food allergy can be divided into three groups: IgE-mediated, non-IgE-mediated, and mixed food allergy. The symptoms will depend on the immunological mechanisms and can be divided into immediate or no immediate, the immediate symptoms appear in the first two hours of intake and the no immediate symptoms after the second hour and up to 72 hours. Diagnosis of food allergy requires a medical history, physical examination and laboratory tests; misdiagnosis can lead to unnecessary elimination diets. The gold standard is the double-blind placebo controlled oral food challenge. The main treatment is food restriction, the nutritional and psychological implications that this entails must be taken into account; Another treatment option is oral immunotherapy, it is recommended in patients who cannot carry out an elimination diet and it has a significant impact on quality of life.
{"title":"Alergia Alimentaria, puntos clave para la práctica clínica","authors":"B. Navarro, O. S. Ramírez, J. A. Hayashi","doi":"10.29262/RAM.V67I1.741","DOIUrl":"https://doi.org/10.29262/RAM.V67I1.741","url":null,"abstract":"Food allergy is an immune reaction that occurs frequently in pediatric age, its prevalence is higher in industrialized countries, affecting 8% of the population, the most frequently involved foods are milk, hen’s egg, soybeans, peanuts, fish, wheat, seafood and tree nuts. Food allergy can be divided into three groups: IgE-mediated, non-IgE-mediated, and mixed food allergy. The symptoms will depend on the immunological mechanisms and can be divided into immediate or no immediate, the immediate symptoms appear in the first two hours of intake and the no immediate symptoms after the second hour and up to 72 hours. Diagnosis of food allergy requires a medical history, physical examination and laboratory tests; misdiagnosis can lead to unnecessary elimination diets. The gold standard is the double-blind placebo controlled oral food challenge. The main treatment is food restriction, the nutritional and psychological implications that this entails must be taken into account; Another treatment option is oral immunotherapy, it is recommended in patients who cannot carry out an elimination diet and it has a significant impact on quality of life.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77570325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号